FDA approval of VYKAT XR for hyperphagia in Prader-Willi Syndrome marks a major milestone for Soleno Therapeutics.

Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the ...

Soleno Therapeutics, Inc. (NASDAQ:SLNO) is one of the. On June 23, TD Cowen analyst Tyler Van Buren began coverage of the com ...

VYKAT XR was approved by the FDA on March 26, 2025, for treating hyperphagia in PWS patients aged 4 and older. Common adverse reactions included hypertrichosis, edema, hyperglycemia, and rash.

VYKAT XR was approved by the U.S. Food and Drug Administration (FDA) on March 26, 2025, and is now commercially available to U.S. patients.

Soleno Therapeutics Inc. (NASDAQ:SLNO) is one of the 10 biotech stocks screaming a buy now. On June 17, Piper Sandler ...

REDWOOD CITY, Calif. - Soleno Therapeutics, Inc. (NASDAQ:SLNO), whose stock has surged 116% over the past year and is trading near its 52-week high of $85.36, presented new data on VYKAT XR (diazoxide ...

A new drug is helping families who've spent years padlocking fridges, chaining garbage cans, and hiding food as their ...

Ali Foley Shenk still remembers the panic when her 10-year-old son, Dean, finished a 20-ounce box of raisins in the seconds ...

What’s becoming clear is that obesity isn’t one disease — it’s many, said Jack Yanovski, a senior obesity researcher at the ...